跳至主要内容
临床试验/NCT01653977
NCT01653977终止不适用

Impact of Early Goal-directed Fluid Therapy in Hypovolemic Patients Undergoing Emergency Surgery A Prospective, Randomised, Open Trial

University Hospital, Geneva2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2010年2月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
20
试验地点
2
主要终点
Delta lactate

研究概览

简要总结

This study compares the safety and efficacy of GDTs using standard pressure-related parameters vs. dynamic hemodynamic indices associated with fluid compartment monitoring, in trauma patients requiring emergency surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults > 18 years
  • Severe hypovolemic condition°
  • Need for emergent interventional procedure under general anesthesia with an expected duration > 120 min.

排除标准

  • Patients responding to early fluid resuscitation (20ml/kg) who don't require a CVC
  • Neurotrauma (Glasgow Coma Score < 12) and/ or medullar trauma
  • Known pregnancy or diagnosed by US or Ct-scan (> 14 weeks)
  • Sustained cardiac arrhythmia (see Logbook P8)
  • Known or diagnosed severe cardiac valvular dysfunction (stenosis, insufficiency) (see Logbook P8)
  • Known or diagnosed intracardiac shunt: interventricular or atrial defect (see Logbook P8)
  • Burn injury > 10%
  • Needed emergency thoracotomy or ABC resuscitation protocol
  • Pre-existing severe liver dysfunction(Child-Pugh class C)
  • Do-not-resuscitate order, died within 48h of admission
  • Ultra-emergent surgery with no further diagnostic investigation.

结局指标

主要结局

Delta lactate

时间窗: From randomization, for the duration of surgery and up to transfer from the operating room to the ICU or recovery room, an expected average of 6 hours.

The primary study endpoint will be the difference between the baseline arterial blood lactate at the time of randomization and the value of the arterial blood lactate at the time of transfer from the emergency operating room (∆ lactate).

次要结局

  • Cardiovascular complications: myocardial infarct or congestive heart failure(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Cerebral complications: stroke(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Pulmonary complications: ALI/ARDS, bronchopneumonia(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Pulmonary complications: respiratory insufficiency necessitating re-intubation(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Surgical complications: re-operation for bleeding or infection(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Total duration of ventilation : days(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Renal complications: infection, urosepsis or renal insufficiency(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Duration of post-operative mechanical ventilation: in hours(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Length of stay in the ICU: in days(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Death(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Length of stay in hospital: in days(Day 1, day 2, day 3 after randomization until hospital discharge or up to 28 days or death, whichever comes first.)
  • Mortality(From randomization up to 28 days)
  • SOFA score measurement(From randomization : day 1, day 2, day 3)
  • Number of unexpected ICU admission(From randomization up to 28 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Pavlovic Gordana, MD

Principal Investigator

University Hospital, Geneva

研究点 (2)

Loading locations...

相似试验